Clinical trials are currently ongoing that test the efficacy of entrectinib (a broad-spectrum kinase inhibitor for NTRKs, ROS, and ALK) in NTRK-rearranged solid tumors including breast cancer (NCT02568267, CT02097810). This evidence concerns the gene ALK and breast carcinoma.